Skip to main content
SpringerLink
Log in

Breast Cancer Screening and Cervical Cancer Prevention in Developing Countries: Strategies for the Future

  • Chapter
  • First Online:
Breast and Gynecological Cancers

Abstract

Breast cancer is increasing 3.1 % annually. It is more deadly and more frequent in young women in developing countries compared to young women in the more developed countries. Important reasons for this increased incidence and lethality are poor nutrition (leading to decreased immunity to resist the advance of cancer), delayed access to health care, and poor quality of care when it is finally available. Early detection of breast cancer is the key to the control of its lethal effects. Increasing breast health awareness and clinical breast examination are key components of a screening program at the present time. Such a strategy is aimed at detecting Stage I and Stage II cancers and downstaging cancers from the now prevalent presentation at Stage III and Stage IV. For the future, however, a low cost methodology needs to be adopted in order to diagnose small node-negative cancers by screening the asymptomatic population. Organized screening mammography is not a feasible option for low and mid-resource countries, even in the future. A combination of low prevalence and the expensive infrastructure needed in terms of the equipment and trained health-care professionals makes this an unrealistic option and a potential drain and diversion of health-care funding resources in developing countries. The background of the situation that is currently in existence, problems thereof, and the potential for the use of whole breast ultrasound screening for breast cancer is discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozao R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461–84.

    Google Scholar 

  2. Pavelic L, Pavelic K, Vuk-Pavelic S. Human mammary and bronchial carcinomas in vivo and in vitro secretion of substances immunologically cross-reactive with insulin. Cancer. 1984;53:2467–71.

    Google Scholar 

  3. Ziegler RG, Anderson WF, Gail MH. Increasing breast cancer incidence in China: the numbers add up. JNCI. 2008;100:1339–41.

    Google Scholar 

  4. Polyak K. Breast cancer: origins and evolution. J Clin Invest. 2007;117:3155–63.

    Google Scholar 

  5. Satyaraj E. Emerging paradigms in immunonutrition. Top Companion Anim Med. 2011;26(1):25–32.

    Google Scholar 

  6. Farmer H, McCabe N, Lord C, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917–21.

    Google Scholar 

  7. Bittner JJ. Some possible effects of nursing on the mammary gland tumor incidence in mice. Science. 1936;84:162.

    Google Scholar 

  8. Ross SR. Mouse mammary tumor virus molecular biology and oncogenesis. Viruses. 2010;2:2000–12.

    Google Scholar 

  9. Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Moustafa A-E. High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. Br J Cancer. 2008;99:404–7.

    Google Scholar 

  10. Kroupis C, Markou A, Vourlidis N, Dionyssiou-Asteriou A, Lianidou ES. Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. Clin Biochem. 2006;39:727–31.

    Google Scholar 

  11. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, et al. Prevalence of genital HPV in the among females in the United States, the National Health and Nutrition Examination Survey, 2003–2006. J Infect Dis. 2011;204(4):566–73.

    Google Scholar 

  12. Shenefelt PD. Nongenital warts. Medscape Reference Drugs Disease & Procedures. 2012. http://emedicine.medscape.com/article/1133317-overview

  13. Khan S, Jaffer NN, Khan MN, Rai MA, Shafiq M, Ali A, et al. Human papillomavirus subtype 16 is common in Pakistani women with cervical carcinoma. Int J Infect Dis. 2007;11(4):313–7.

    Google Scholar 

  14. Center for Communicable Diseases. Epidemiology and prevention of vaccine-preventable diseases: human papillomavirus. The pink book: course textbook, Ch 10, 12th ed. Washington, DC: Public Health Foundation; 2012. p. 139–49.

    Google Scholar 

  15. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101–5.

    Google Scholar 

  16. Barth AJ Jr, Gibson GR, Mott LA, Becher RD, Poplack SP. Detection of breast cancer on screening mammography allows patients to be treated with less-toxic therapy. AJR. 2005;184:325–9.

    Google Scholar 

  17. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:727–37.

    Google Scholar 

  18. Duffy SW, Tabár L, Vitak B, Warwick J. Tumor Size and breast cancer detection: what might be the effect of a less sensitive screening tool than mammography? Breast J. 2006; 12 Suppl 1:S91–5.

    Google Scholar 

  19. Yu Y-H, Wei W, Liu J-L. Diagnostic value of fine-needle aspiration biopsy for breast mass: a systematic review and meta-analysis. BMC Cancer. 2012;12:41.

    Google Scholar 

  20. Ljung BM, Drejet A, Chiampi N, Jeffrey J, Goodson WH 3rd, Chew K, et al. Diagnostic accuracy of fine-needle aspiration biopsy is determined by ­physician training in sampling technique. Cancer. 2011;93(4):263–8.

    Google Scholar 

  21. Tabár L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011;260:658–63.

    Google Scholar 

  22. Keen C. SSPs take on larger role in digital mammography. Hefty data sets and multiple prior images threaten to put a strain on standard storage and network options. Diagnostic Imaging. 2005;27:S-23–31. http://www.diagnosticimaging.com/display/article/113619/1197582. Cited 17 Aug 2012.

  23. Kelly KM, Dean J, Comulada WS, Lee S-J. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. Eur Radiol. 2010;20:734–42.

    Google Scholar 

  24. Elmore JG, Armstrong K, Lehman CD, et al. Screening for breast cancer. JAMA. 2005;293:1245–56.

    Google Scholar 

  25. Nothacker M, Duda V, Hahn M, et al. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue: a systematic review. BMC Cancer. 2009;9:1–9.

    Google Scholar 

  26. Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs. mammography alone in women with elevated risk of breast cancer. JAMA. 2008;299:2151–63.

    Google Scholar 

  27. Tohno E, Ueno E, Watanabe H. Ultrasound screening of breast cancer. Breast Cancer. 2009;16:18–22.

    Google Scholar 

  28. Kuhl CK. The “coming of age” of nonmammographic screening for breast cancer. JAMA. 2008;299:2203–5.

    Google Scholar 

  29. Tohno E, Takahashi H, Tamada T, Fujimoto Y, Yasuda H, Ohuchi N. Educational program and testing using images for the standardization of breast cancer screening by ultrasonography. Breast Cancer. 2012;19(2):138–46.

    Google Scholar 

  30. Kelly KM, Richwald GA. Automated whole-breast ultrasound: advancing the performance of breast cancer screening. Semin Ultrasound CT MRI. 2011;32:273–80.

    Google Scholar 

  31. Tabár L. Personal Communication. Santa Barbara, California. Summer 2011.

    Google Scholar 

  32. WHO International Agency for Research on Cancer. Breast cancer incidence and mortality worldwide in 2008 summary. 2008. http://globocan.iarc.fr/factsheets/cancers/breast.asp. Cited 17 Aug 2012.

References

  1. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57(1):7–28.

    Article  PubMed  Google Scholar 

  2. Burchell AN, Winer RL, de Sanjose S, Franco EL. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006;24 Suppl 3:S3/52–61.

    Google Scholar 

  3. WHO. Initiative for vaccine research (IVR)—viral cancer—HPV. World Health Organization. 2011. http://www.who.int/vaccine_research/diseases/viral_cancers/en/index3.html. Cited 30 Jun 2012.

  4. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–43.

    Article  PubMed  CAS  Google Scholar 

  5. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.

    Article  PubMed  CAS  Google Scholar 

  6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon: International Agency for Research on Cancer; 2011. http://globocan.iarc.fr. Cited 30 Jun 2012.

  7. Update on Human Papillomavirus (HPV) Vaccines. CCDR (Canada communicable disease report) 2012;38:1–62.

    Google Scholar 

  8. WHO. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals. Geneva: WHO Press; 2007. p. 43.

    Google Scholar 

  9. WHO/ICO. Human papillomavirus and related cancers in world. Summary report update. October 9, 2009. WHO/ICO Information Centre on HPV and Cervical Cancer. 2009.

    Google Scholar 

  10. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24 Suppl 3:S3/11–25.

    Google Scholar 

  11. WHO. Human papillomavirus vaccines. WHO position paper. Weekly Epidemiological Record 2009;15:118–31.

    Google Scholar 

  12. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085–92.

    Article  PubMed  Google Scholar 

  13. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24.

    Google Scholar 

  14. FDA. Vaccines, blood & biologics. Vaccines. Approved products FDA; 2012. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172678.htm. Cited 2012 Jul 20, 2012.

  15. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–43.

    Article  PubMed  CAS  Google Scholar 

  16. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459–66.

    Article  PubMed  CAS  Google Scholar 

  17. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27.

    Google Scholar 

  18. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14.

    Article  PubMed  CAS  Google Scholar 

  19. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.

    Article  PubMed  CAS  Google Scholar 

  20. Villa LL. HPV prophylactic vaccination: the first years and what to expect from now. Cancer Lett. 2011;305(2):106–12.

    Article  PubMed  CAS  Google Scholar 

  21. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic adrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271–8.

    Article  PubMed  Google Scholar 

  22. Stokley S, Cohn A, Dorell C, Hariri S, Yankey D, Messonnier N, et al. Adolescent vaccination-coverage levels in the United States: 2006–2009. Pediatrics. 2011;128(6):1078–86.

    Article  PubMed  Google Scholar 

  23. Finn A. Strategy options for HPV vaccine delivery in EU countries. Guidance for the introduction of HPV vaccines in EU countries. Stockholm: European Centre for Disease Prevention and Control; 2008. p. 30–6.

    Google Scholar 

  24. Garland SM, Skinner SR, Brotherton JM. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med. 2011;53 Suppl 1:S29–35.

    Article  PubMed  Google Scholar 

  25. Immunise Australia Program. Human Papillomavirus (HPV). Information about the National Human Papillomavirus (HPV) Vaccination Program funded under the Immunise Australia Program.: Australian Government. Depatment of Health and Aging; 2011 [updated Apr 04, 2011]; http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv#figure2. Cited 30 Jun 2012.

  26. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro surveillance: bulletin europeen sur les maladies transmissibles = European communicable disease bulletin 2010;15(47).

    Google Scholar 

  27. HPV Vaccine: Implementation and Financing Policy. The Henry J. Kaiser Family Foundation. 2007. http://www.kff.org/womenshealth/upload/7602.pdf. Cited 2012.

  28. The HPV Vaccine: Access and Use in the U.S.: The Henry J. Kaiser Family Foundation. 2011. http://www.kff.org/womenshealth/7602.cfm. Cited 2012.

  29. IARC. Making cervical cancer vaccines widely available in developing countries: cost and financing issues. IARC. http://screening.iarc.fr/doc/IAVI_PATH_HPV_financing_brief.pdf. Cited 2012.

  30. Smith LM, Brassard P, Kwong JC, Deeks SL, Ellis AK, Levesque LE. Factors associated with initiation and completion of the quadrivalent human papillomavirus vaccine series in an Ontario cohort of grade 8 girls. BMC Public Health. 2011;11:645.

    Article  PubMed  Google Scholar 

  31. Colucci R, Hryniuk W, Savage C. HPV vaccination programs in Canada: Are we hitting the mark? Report Card on Cancer in Canada [Internet]. 2010 Aug 11, 2012. Available from: http://www.canceradvocacy.ca/reportcard/2008/HPV%20Vaccination%20Programs%20in%20Canada.pdf.

  32. Progress toward implementation of human papillomavirus vaccination--the Americas, 2006–2010. MMWR Morbidity and mortality weekly report 2011;60(40):1382–4.

    Google Scholar 

  33. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ. 2011;89(11):821–30B.

    Article  PubMed  Google Scholar 

  34. Saxenian H. HPV Vaccine Adoption in Developing Countries: Cost and Financing Issues: International AIDS Vaccine Initiative/Program for Appropriate Technology in Health (PATH). http://www.iavi.org/HPVreport. Cited 2007.

  35. Garland SM. Human papillomavirus vaccination: where to now? Sex Transm Infect. 2011;87 Suppl 2:ii23–4.

    Article  PubMed  Google Scholar 

  36. GAVI Alliance. http://www.gavialliance.org/. Cited 2012.

  37. GAVI. Human papillomavirus vaccine support. GAVI Alliance. http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccine-support/. Cited 2012.

  38. PAHO. PAHO Revolving Fund. Pan American Health Organization; Available from: http://new.paho.org/hq/index.php?option=com_content&task=view&id=1864&Itemid=2234&lang=en.

  39. Bonanni P, Levi M, Latham NB, Bechini A, Tiscione E, Lai P, et al. An overview on the implementation of HPV vaccination in Europe. Hum Vaccin. 2011;7(Suppl):128–35.

    Article  PubMed  Google Scholar 

  40. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health. 2012;12:370.

    Article  PubMed  Google Scholar 

  41. GAP. Gardasil Access Program. 2012. http://www.gardasilaccessprogram.org/section/141. Cited 4 Nov 2012.

Download references

Author information

Authors and Affiliations

  1. Pasadena Breast Ultrasound Center, Pasadena, CA, 91106, USA

    Kevin M. Kelly

  2. Woman’s Center for Breast Care and MRI, Woman’s Hospital of Texas, Houston, TX, 77054, USA

    Mahesh K. Shetty

  3. Center for Research Support, Teaching and Research Institute, Barretos Cancer Hospital, Barretos, 14784-400, Brazil

    José Humberto Tavares Guerreiro Fregnani

Authors
  1. Kevin M. Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahesh K. Shetty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José Humberto Tavares Guerreiro Fregnani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mahesh K. Shetty .

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, Baylor Plaza 1, Houston, 77030, Texas, USA

    Mahesh K. Shetty

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Kelly, K.M., Shetty, M.K., Fregnani, J.H.T.G. (2013). Breast Cancer Screening and Cervical Cancer Prevention in Developing Countries: Strategies for the Future. In: Shetty, M. (eds) Breast and Gynecological Cancers. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1876-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1876-4_16

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-1875-7

  • Online ISBN: 978-1-4614-1876-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation